TSMC Rejects Intel Investment and Partnership Rumors
Top chipmaker TSMC denied rumors of an investment or partnership with struggling Intel. TSMC stated it has not entered talks for joint ventures or technology transfer.
NOTRELOAD AI
Enanta Stock Drops After Mixed Results from RSV Drug Trial
Enanta Pharmaceuticals' experimental RSV drug caused stock market disappointment after failing its main goal (reducing symptom time). However, the trial showed success in important secondary areas, like clearing the virus faster.
FDA Greenlights RAPT's Next-Gen Food Allergy Treatment Trial
FDA OKs major trial (prestIgE) for RPT904, a next-gen anti-IgE drug. It will treat ~100 people allergic to peanut, milk, or egg. The goal is a better, safe therapeutic option by blocking IgE, the key driver of these allergies.
China Robotaxi 'Inflection Point': Citi Initiates Coverage
Citi initiated "Buy" coverage on leading China robotaxi operators, WeRide and Pony AI, predicting massive market growth through 2035, signaling an industry inflection point.
Deutsche Bank Upgrades Lam Research to Buy: 'Cyclical and Secular Tailwinds'
Deutsche Bank upgraded Lam Research to Buy, citing strong market trends including improved memory supply/demand and momentum at key foundries.
Genmab's $8 Billion Move: Acquiring Merus to Lead the Next Wave of Cancer Antibody Therapeutics
Denmark's Genmab is acquiring Dutch drugmaker Merus for $8 billion to secure petosemtamab, a late-stage, breakthrough treatment for head and neck cancer, bolstering Genmab's proprietary oncology pipeline and accelerating its evolution into a global biotechnology leader.